KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $83,361.78 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $83,361.78. Following the completion of the transaction, the insider directly owned 138,983 shares of the company’s stock, valued at $2,163,965.31. This trade represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $15.76 on Friday. The company has a market cap of $796.60 million, a PE ratio of -3.99 and a beta of -0.19. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The firm has a 50-day simple moving average of $15.50 and a 200 day simple moving average of $13.97. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on KALV. HC Wainwright increased their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Citizens Jmp cut their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, Needham & Company LLC increased their price objective on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals during the 3rd quarter worth $24,360,000. Vestal Point Capital LP raised its stake in shares of KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares in the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after purchasing an additional 905,053 shares during the period. Finally, Elmind Capital LP acquired a new stake in KalVista Pharmaceuticals in the fourth quarter worth about $12,941,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.